Gilead Sciences (GILD) Other financing activities (2009 - 2026)

Gilead Sciences (GILD) has reported Other financing activities for 18 consecutive years, with -$350.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities fell 446.88% year-over-year to -$350.0 million; the trailing twelve-month figure through Jun 2026 stood at -$729.0 million (down 97.56% YoY), and the FY2025 full-year result was -$440.0 million, down 56.58% from the prior year.
• Other financing activities fell to -$350.0 million in Q2 2026 per GILD's latest filing, from -$179.0 million in the prior quarter.
• Across five years, Other financing activities topped out at -$14.0 million in Q2 2022 and bottomed at -$350.0 million in Q2 2026.
• Historically, Other financing activities has averaged -$94.6 million across 5 years, with a median of -$71.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Other financing activities climbed 14.07% in 2024, then sank 446.88% in 2026.
• Over 5 years, Other financing activities stood at -$23.0 million in 2022, then plunged by 47.83% to -$34.0 million in 2023, then plunged by 38.24% to -$47.0 million in 2024, then tumbled by 34.04% to -$63.0 million in 2025, then sank by 455.56% to -$350.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$350.0 million, -$179.0 million, and -$63.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.